Literature DB >> 19674539

Development of an experimental inactivated PRRSV vaccine that induces virus-neutralizing antibodies.

Merijn Vanhee1, Peter L Delputte, Iris Delrue, Marc F Geldhof, Hans J Nauwynck.   

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV) can induce reproductive disorders and is involved in the porcine respiratory disease complex, causing tremendous economic losses to the swine industry. Inactivated PRRSV vaccines are preferred over attenuated vaccines because of their safety and flexibility towards emerging virus strains, but the efficacy of current inactivated PRRSV vaccines is questionable. In this study, experimental inactivated PRRSV vaccines were developed, based on two formerly optimized inactivation procedures: UV irradiation and treatment with binary ethylenimine (BEI). In a first experiment, it was shown that vaccination with UV- or BEI-inactivated virus in combination with Incomplete Freund's Adjuvant induced virus-specific antibodies and strongly primed the virus-neutralizing (VN) antibody response. Subsequently, the influence of adjuvants on the immunogenicity of neutralizing epitopes on the inactivated virus was investigated. It was shown that vaccination with BEI-inactivated virus in combination with a commercial oil-in-water adjuvant induced high titers (3.4 log(2)) of VN antibodies in 6/6 pigs, instead of only priming the neutralizing antibody response. After challenge, neutralizing antibody titers in these vaccinated animals rose to a mean value of 5.5 log(2), and the duration of the viremia was reduced to an average of 1 week. This study shows that, by the use of an optimized inactivation procedure and a suitable adjuvant, inactivated PRRSV vaccines can be developed that induce VN antibodies and offer partial protection upon challenge.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19674539     DOI: 10.1051/vetres/2009046

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  32 in total

1.  Evaluation of the new commercial recombinant chimeric subunit vaccine PRRSFREE in challenge with heterologous types 1 and 2 porcine reproductive and respiratory syndrome virus.

Authors:  Jiwoon Jeong; Changhoon Park; Kyuhyung Choi; Chanhee Chae
Journal:  Can J Vet Res       Date:  2017-01       Impact factor: 1.310

2.  Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts.

Authors:  Taehwan Oh; Hanjin Kim; Kee Hwan Park; Jiwoon Jeong; Ikjae Kang; Siyeon Yang; Chanhee Chae
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

3.  The crystal structure of porcine reproductive and respiratory syndrome virus nonstructural protein Nsp1beta reveals a novel metal-dependent nuclease.

Authors:  Fei Xue; Yuna Sun; Liming Yan; Cong Zhao; Ji Chen; Mark Bartlam; Xuemei Li; Zhiyong Lou; Zihe Rao
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

4.  A variable region in GP4 of European-type porcine reproductive and respiratory syndrome virus induces neutralizing antibodies against homologous but not heterologous virus strains.

Authors:  Merijn Vanhee; Sarah Costers; Wander Van Breedam; Marc F Geldhof; Jan Van Doorsselaere; Hans J Nauwynck
Journal:  Viral Immunol       Date:  2010-08       Impact factor: 2.257

5.  Protective humoral immune response induced by an inactivated porcine reproductive and respiratory syndrome virus expressing the hypo-glycosylated glycoprotein 5.

Authors:  Jung-Ah Lee; Byungjoon Kwon; Fernando A Osorio; Asit K Pattnaik; Nak-Hyung Lee; Sang-Won Lee; Seung-Yong Park; Chang-Seon Song; In-Soo Choi; Joong-Bok Lee
Journal:  Vaccine       Date:  2014-05-09       Impact factor: 3.641

6.  Development and validation of an assay to detect porcine reproductive and respiratory syndrome virus-specific neutralizing antibody titers in pig oral fluid samples.

Authors:  Kang Ouyang; Basavaraj Binjawadagi; Apisit Kittawornrat; Chris Olsen; Jagadish Hiremath; Nadia Elkalifa; Rose Schleappi; Jianmin Wu; Jeffrey Zimmerman; Gourapura J Renukaradhya
Journal:  Clin Vaccine Immunol       Date:  2013-06-19

7.  Correlation of Neutralizing Antibodies (NAbs) between Sows and Piglets and Evaluation of Protectability Associated with Maternally Derived NAbs in Pigs against Circulating Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) under Field Conditions.

Authors:  Fu-Chun Hsueh; Sheng-Yuan Wang; Wei-Hao Lin; Chuen-Fu Lin; Chen-Yu Tsai; Chin-Wen Huang; Ning Sun; Ming-Tang Chiou; Chao-Nan Lin
Journal:  Vaccines (Basel)       Date:  2021-04-21

8.  Interaction of the European genotype porcine reproductive and respiratory syndrome virus (PRRSV) with sialoadhesin (CD169/Siglec-1) inhibits alveolar macrophage phagocytosis.

Authors:  Miet I De Baere; Hanne Van Gorp; Peter L Delputte; Hans J Nauwynck
Journal:  Vet Res       Date:  2012-05-25       Impact factor: 3.683

9.  The assessment of efficacy of porcine reproductive respiratory syndrome virus inactivated vaccine based on the viral quantity and inactivation methods.

Authors:  Hyunil Kim; Hye Kwon Kim; Jung Ho Jung; Yoo Jung Choi; Jiho Kim; Chang Gyu Um; Su Bin Hyun; Sungho Shin; Byeongchun Lee; Goo Jang; Bo Kyu Kang; Hyoung Joon Moon; Dae Sub Song
Journal:  Virol J       Date:  2011-06-27       Impact factor: 4.099

10.  Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.

Authors:  Marc F Geldhof; Merijn Vanhee; Wander Van Breedam; Jan Van Doorsselaere; Uladzimir U Karniychuk; Hans J Nauwynck
Journal:  BMC Vet Res       Date:  2012-10-03       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.